Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953412 | 0.83 | CHRNA7 (0.37) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10345271 | 0.82 | CHRNA7 (0.37) | ALDH1A1 | |
| SCHEMBL28914522 | 0.82 | ALDH1A1 (0.45) | ALDH1A1RECQLKCNA3ALOX15LMNA | |
| SCHEMBL2343249 | 0.81 | OPRM1 (0.41) | ALDH1A1RECQLKCNA3ALOX15 | |
| Hydrochloric Acid SCHEMBL7981065 | 0.80 | OPRM1 (0.40) | ALDH1A1RECQLKCNA3ALOX15 | |
| SCHEMBL11013902 | 0.71 | ALDH1A1 (0.42) | ALDH1A1RECQLKCNA3ALOX15LMNA | |
| SCHEMBL1740342 | 0.69 | OPRL1 (0.46) | — | |
| SCHEMBL10345184 | 0.68 | OPRL1 (0.56) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL847010 | 0.68 | LMNA (0.40) | ALDH1A1RECQLKCNA3ALOX15LMNA | |
| SCHEMBL10345211 | 0.67 | TSHR (0.50) | ALDH1A1LMNACYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | ALDH1A1 1234/4885RECQL 1332/4885KCNA3 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.